Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US11090306B2 · kind B2 · utility
3Cited by
25References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 16, 2019 |
| Grant date | Aug 17, 2021 |
| Priority date | — |
| Expiry date | Dec 31, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/695
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.